Systemic sclerosis & Raynaud's
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
Authors' conclusion
In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.
Study context
- Population
- Subjects with SSc and fibrotic ILD of ≥10% extent on high-resolution CT, with or without risk factors for rapid forced vital capacity (FVC) decline (early SSc, elevated inflammatory markers, significant skin fibrosis)
- Comparison
- Nintedanib vs placebo
- Primary endpoint
- Rate of decline in FVC
- Follow-up
- 52 weeks
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
Rate of FVC decline, placebo, by risk-factor subgroup
- Placebo, <18 months since first non-Raynaud symptom
- −167.8 mL/year
- Placebo, elevated inflammatory markers
- −100.7 mL/year
- Placebo, modified Rodnan skin score (mRSS) 15-40
- −121.7 mL/year
- Placebo, mRSS ≥18
- −131.7 mL/year
- Placebo, all subjects
- −93.3 mL/year
Original publication
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →